A successful small-scale, phase-two clinical trial, announced by Harvest One on July 24, 2018 showed that a CBD drug developed by its subsidiary Satipharm reduced seizures by 82%.
The study was conducted by Israel-based Phytotech Therapeutics, which is was recently purchased by Harvest One from Australia-based MMJ.
MMJ is Harvest One’s 30% owner.
The drug developed by Harvest One’s Satipharm is significant, because UK-based GW Pharmaceuticals recently made history with its patented epilepsy drug – the very first cannabis-based drug to get U.S. FDA approval.
Epidiolex is expected to sell for around US$37,000 for a one-year supply.
GW Pharma trades on the NASDAQ around the US$140 mark.
Satipharm’s clinical trails for its epilepsy medication show that it “compares favourably” to GW Pharmaceutical’s Epilpodex.
The 82 per cent reduction in monthly seizures “have the potential to be a life-altering event for these patients and their families,” said principal investigator Prof. Uri Kramer, Director of Pediatric Epilepsy Service at Tel Aviv Sourasky Medical Center.